Sickle Cell Disease Survival Rises With Gene Therapy and Better Care
Survival for adults with sickle cell disease has improved dramatically, with life expectancy more than tripling over the past five decades and many patients now living into their 60s. Two approved gene therapies offer a potential cure for some patients, though the treatments are intensive and available at limited centers. Improved supportive care also contributes to longer and better-quality lives.
Expanded Detail
EXPANDED:
Over 50 years, sickle cell disease survival has risen from teenage estimates—some as low as 14—to a point where, by 2022, half of patients died
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
FDA approves GSK hepatitis B therapy with broader cure reach · Drug development
Micropeptide Therapy Slows Age-Related Vascular Calcification · Drug development
FDA clears GSK and Ionis hepatitis B therapy with functional-cure goal · Infectious disease
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Improving Survival for Adults With Sickle Cell Disease.” Browse more stories.